Enliven Therapeutics Net Worth
Enliven Therapeutics Net Worth Breakdown | ELVN |
Enliven Therapeutics Net Worth Analysis
Enliven Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Enliven Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Enliven Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Enliven Therapeutics' net worth analysis. One common approach is to calculate Enliven Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Enliven Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Enliven Therapeutics' net worth. This approach calculates the present value of Enliven Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Enliven Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Enliven Therapeutics' net worth. This involves comparing Enliven Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Enliven Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Enliven Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Enliven Therapeutics' net worth research are outlined below:
| Enliven Therapeutics generated a negative expected return over the last 90 days | |
| Enliven Therapeutics has high historical volatility and very poor performance | |
| Enliven Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (71.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enliven Therapeutics generates negative cash flow from operations | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Enliven Therapeutics CFO sells 70,177 in stock - MSN |
Enliven Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Enliven Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enliven Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Enliven Therapeutics Target Price Consensus
Enliven target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Enliven Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Enliven analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Enliven stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Enliven Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEnliven Therapeutics Target Price Projection
Enliven Therapeutics' current and average target prices are 21.86 and 37.86, respectively. The current price of Enliven Therapeutics is the price at which Enliven Therapeutics is currently trading. On the other hand, Enliven Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Enliven Therapeutics Market Quote on 1st of February 2025
Target Price
Analyst Consensus On Enliven Therapeutics Target Price
Follow Enliven Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.07 B.Market Cap |
|
Project Enliven Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.31) | (0.32) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.33) | (0.32) |
When accessing Enliven Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Enliven Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Enliven Therapeutics' profitability and make more informed investment decisions.
Evaluate Enliven Therapeutics' management efficiency
Enliven Therapeutics has return on total asset (ROA) of (0.2137) % which means that it has lost $0.2137 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3098) %, meaning that it created substantial loss on money invested by shareholders. Enliven Therapeutics' management efficiency ratios could be used to measure how well Enliven Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of February 2025, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, Enliven Therapeutics' Total Assets are very stable compared to the past year. As of the 1st of February 2025, Other Current Assets is likely to grow to about 15.7 M, while Non Current Assets Total are likely to drop about 3.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.96 | 8.35 | |
| Tangible Book Value Per Share | 7.96 | 8.35 | |
| Enterprise Value Over EBITDA | (5.50) | (5.23) | |
| Price Book Value Ratio | 1.80 | 1.89 | |
| Enterprise Value Multiple | (5.50) | (5.23) | |
| Price Fair Value | 1.80 | 1.89 | |
| Enterprise Value | 352.9 M | 370.6 M |
The leadership approach at Enliven Therapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enliven Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enliven Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enliven Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enliven Therapeutics Corporate Filings
F4 | 29th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Enliven Therapeutics Earnings Estimation Breakdown
The calculation of Enliven Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Enliven Therapeutics is estimated to be -0.3975 with the future projection ranging from a low of -0.3975 to a high of -0.3975. Please be aware that this consensus of annual earnings estimates for Enliven Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.4 Lowest | Expected EPS | -0.4 Highest |
Enliven Therapeutics Earnings Projection Consensus
Suppose the current estimates of Enliven Therapeutics' value are higher than the current market price of the Enliven Therapeutics stock. In this case, investors may conclude that Enliven Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Enliven Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 8 | 86.97% | -0.4782 | -0.3975 | -1.89 |
Enliven Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Enliven Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Enliven Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Enliven Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Enliven Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Enliven Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Enliven Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Enliven Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Enliven Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.5 | -0.4782 | 0.0218 | 4 | ||
2024-08-13 | 2024-06-30 | -0.55 | -0.41 | 0.14 | 25 | ||
2024-05-14 | 2024-03-31 | -0.57 | -0.54 | 0.03 | 5 | ||
2024-03-14 | 2023-12-31 | -0.54 | -0.47 | 0.07 | 12 | ||
2023-11-09 | 2023-09-30 | -0.47 | -0.51 | -0.04 | 8 | ||
2023-08-10 | 2023-06-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2023-05-11 | 2023-03-31 | -0.63 | -0.8 | -0.17 | 26 | ||
2023-02-10 | 2022-12-31 | -0.786 | 1.21 | 1.996 | 253 | ||
2022-10-25 | 2022-09-30 | -1 | -0.72 | 0.28 | 28 | ||
2022-08-03 | 2022-06-30 | -2.05 | -1.76 | 0.29 | 14 | ||
2022-05-06 | 2022-03-31 | -2.31 | -2.24 | 0.07 | 3 | ||
2022-03-15 | 2021-12-31 | -3 | -2.12 | 0.88 | 29 | ||
2021-11-09 | 2021-09-30 | -3.38 | -2.2 | 1.18 | 34 | ||
2021-08-06 | 2021-06-30 | -3.2 | -2.96 | 0.24 | 7 | ||
2021-05-11 | 2021-03-31 | -3.34 | -2.32 | 1.02 | 30 | ||
2021-03-05 | 2020-12-31 | -3.35 | -2.24 | 1.11 | 33 | ||
2020-11-05 | 2020-09-30 | -3.21 | -2.88 | 0.33 | 10 | ||
2020-08-14 | 2020-06-30 | -2.25 | -2.36 | -0.11 | 4 | ||
2020-05-07 | 2020-03-31 | -2.94 | -17.24 | -14.3 | 486 | ||
2020-03-11 | 2019-12-31 | 0 | -0.68 | -0.68 | 0 | ||
2019-10-08 | 2019-09-30 | 0 | -0.32 | -0.32 | 0 |
Enliven Therapeutics Corporate Executives
Elected by the shareholders, the Enliven Therapeutics' board of directors comprises two types of representatives: Enliven Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enliven. The board's role is to monitor Enliven Therapeutics' management team and ensure that shareholders' interests are well served. Enliven Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enliven Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Lyssikatos | CoFounder Officer | Profile | |
| Benjamin Hohl | CFO Development | Profile | |
| Anish PharmD | CoFounder COO | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.